menu
    • menu
    [{"orgOrder":0,"company":"Elysium Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"O2P Hydrocodone Prodrug","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Elysium Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Elysium Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Elysium Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Elysium Therapeutics","sponsor":"Medpace, Inc | Charles River Laboratories | National Institute on Drug Abuse | Ohio Third Frontier","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ETR028","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Elysium Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elysium Therapeutics \/ Medpace, Inc | Charles River Laboratories | National Institute on Drug Abuse | Ohio Third Frontier","highestDevelopmentStatusID":"6","companyTruncated":"Elysium Therapeutics \/ Medpace, Inc | Charles River Laboratories | National Institute on Drug Abuse | Ohio Third Frontier"},{"orgOrder":0,"company":"Elysium Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Elysium Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection, Prolonged Release","sponsorNew":"Elysium Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Elysium Therapeutics \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Elysium Therapeutics

    Menu

    Elysium Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Elysium Therapeutics

                            U.S.A arrow
                            ESCRS
                            Not Confirmed

                            Elysium Therapeutics

                            U.S.A arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Naloxone Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Elysium Completes FDA Pre-IND For Tech To Combat Fentanyl Overdose

                            Details : SOOPR (naloxone) is an opioid receptor antagonist indicated in the reversal of opioid overdoses.

                            Product Name : SOOPR

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 20, 2025

                            Lead Product(s) : Naloxone Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Elysium Therapeutics

                            U.S.A arrow
                            ESCRS
                            Not Confirmed

                            Elysium Therapeutics

                            U.S.A arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : O2P Hydrocodone Prodrug

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Elysium Reports Human Proof-of-Concept Data for O2P Hydrocodone Prodrug for Acute Pain

                            Details : ETR028, first- and best-in-class, oral-overdose protected (O2P) hydrocodone prodrug being developed for the treatment of moderate-to-severe acute pain.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 03, 2024

                            Lead Product(s) : O2P Hydrocodone Prodrug

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Elysium Therapeutics

                            U.S.A arrow
                            ESCRS
                            Not Confirmed

                            Elysium Therapeutics

                            U.S.A arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ETR028

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Medpace, Inc | Charles River Laboratories | National Institute on Drug Abuse | Ohio Third Frontier

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluate the Safety and Pharmacokinetic Profile of ETR028 and ETR029 in Healthy Adult Subjects

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 07, 2022

                            Lead Product(s) : ETR028

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Medpace, Inc | Charles River Laboratories | National Institute on Drug Abuse | Ohio Third Frontier

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth